Patents Assigned to C4 Therapeutics, Inc.
-
Publication number: 20250115580Abstract: The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.Type: ApplicationFiled: December 13, 2024Publication date: April 10, 2025Applicant: C4 THERAPEUTICS, INC.Inventors: Christopher G. Nasveschuk, Katrina L. Jackson, Yanke Liang, Martin Duplessis, Mark E. Fitzgerald, Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Daniela Krummenacher, Piergiorgio Francesco Tommaso Pettazzoni, Juergen Wichmann
-
Publication number: 20250101037Abstract: This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.Type: ApplicationFiled: December 9, 2024Publication date: March 27, 2025Applicant: C4 THERAPEUTICS, INC.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Martin Duplessis, Chi-Li Chen
-
Publication number: 20250084055Abstract: The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.Type: ApplicationFiled: August 15, 2024Publication date: March 13, 2025Applicant: C4 THERAPEUTICS, INC.Inventors: Roger Norcross, Adrian Britschgi, Fabian Dey, Annick Goergler, Eric Andre Kusznir, Moreno Attilio Wichert
-
Publication number: 20250084081Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.Type: ApplicationFiled: November 12, 2024Publication date: March 13, 2025Applicant: C4 THERAPEUTICS, INC.Inventors: Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap
-
Publication number: 20250057957Abstract: This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.Type: ApplicationFiled: July 16, 2024Publication date: February 20, 2025Applicant: C4 THERAPEUTICS, INC.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Kiel Lazarski, Ryan E. Michael
-
Patent number: 12180225Abstract: This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.Type: GrantFiled: October 3, 2022Date of Patent: December 31, 2024Assignee: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Martin Duplessis, Chi-Li Chen
-
Publication number: 20240398959Abstract: This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.Type: ApplicationFiled: April 22, 2024Publication date: December 5, 2024Applicant: C4 THERAPEUTICS, INC.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Kiel Lazarski, Gesine Kerstin Veits, Harit U. Vora
-
Patent number: 12157735Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.Type: GrantFiled: October 13, 2022Date of Patent: December 3, 2024Assignee: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap
-
Publication number: 20240391912Abstract: An advantageous morphic form of Compound 1 which is also known as CFT7455 and is (S)-3-(6-(4-(morpholinomethyl)benzyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione and methods to prepare Compound 1 for therapeutic applications are provided. This invention also provides new dosage regimens for administering Compound 1.Type: ApplicationFiled: August 7, 2024Publication date: November 28, 2024Applicant: C4 THERAPEUTICS, INC.Inventors: James A. Henderson, Matthew J. Schnaderbeck, Minsheng He, Danmei Dai, He Li, Bing Hu, Yu Zhang, Man Ding, Siyi Jiang, Meiqi Li, Juanjuan Shi
-
Patent number: 12049464Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.Type: GrantFiled: September 1, 2022Date of Patent: July 30, 2024Assignee: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap
-
Patent number: 12048748Abstract: This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.Type: GrantFiled: November 11, 2021Date of Patent: July 30, 2024Assignee: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Kiel Lazarski, Ryan E. Michael
-
Patent number: 12048747Abstract: This invention provides amine-linked C3-glutarimide Degronimers for therapeutic applications as described further herein, and methods of use and compositions thereof as well as methods for their preparation, wherein the C3-glutarimide Degronimers have the formula:Type: GrantFiled: December 14, 2020Date of Patent: July 30, 2024Assignee: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Chi-Li Chen, Martin Duplessis, Minsheng He, Kiel Lazarski
-
Publication number: 20240245677Abstract: Selected BRD9 protein degradation compounds and morphic forms thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.Type: ApplicationFiled: March 8, 2024Publication date: July 25, 2024Applicant: C4 THERAPEUTICS, INC.Inventors: Katrina L. Jackson, Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap, Minsheng He, Robert T. Yu, Matthew J. Schnaderbeck, Kathleen Neville, Siyi Jiang, Meiqi Li, Qianwei Liu, Manjie Zheng, Jia Li, Liwei Zhang
-
Publication number: 20240199638Abstract: The present invention provides selected glutarimides which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.Type: ApplicationFiled: October 30, 2023Publication date: June 20, 2024Applicant: C4 Therapeutics, Inc.Inventors: Roger Norcross, Annick Goergler, Philipp Schmid, Fabian Dey, Eric Andre Kusznir
-
Publication number: 20240199581Abstract: The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.Type: ApplicationFiled: December 8, 2023Publication date: June 20, 2024Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveshuk, Katrina L. Jackson, Yanke Liang, Robert T. Yu, Martin Duplessis, Mark E. Fitzgerald, Victoria Garza, Andrew Charles Good, Morgan Welzel O'Shea, Gesine Kerstin Veits, Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Daniela Krummenacher, Piergiorgio Franceso Tommaso Pettazzoni, Juergen Wichmann
-
Patent number: 11992531Abstract: This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.Type: GrantFiled: November 30, 2020Date of Patent: May 28, 2024Assignee: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Kiel Lazarski, Gesine Kerstin Veits, Harit U. Vora
-
Publication number: 20240158418Abstract: The invention provides for the treatment of mutant epidermal growth factor receptor (EGFR) mediated cancer that has metastasized to the brain or other area of the central nervous system with a compound that degrades a mutant form of EGFR via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The invention also provides advantageous drug combinations for the treatment of such cancer that include a compound herein that degrades a mutant form of EGFR in combination with a second anti-cancer agent.Type: ApplicationFiled: November 21, 2023Publication date: May 16, 2024Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
-
Publication number: 20240109889Abstract: The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.Type: ApplicationFiled: September 19, 2023Publication date: April 4, 2024Applicant: C4 Therapeutics, Inc.Inventors: Roger Norcross, Annick Goergler, Fabian Dey, Eric Andre Kusznir
-
Publication number: 20240076300Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.Type: ApplicationFiled: May 8, 2023Publication date: March 7, 2024Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
-
Publication number: 20240051953Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.Type: ApplicationFiled: October 13, 2022Publication date: February 15, 2024Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap
